ClinicalTrials.gg
CompletedNCT02696707OTT 15-05Updated Dec 18, 2025Results posted

An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer

A Phase 4 interventional study of LVEF 3 month and LVEF 4 month in Breast Cancer, sponsored by Ottawa Hospital Research Institute. Completed at 4 sites in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Ottawa Hospital Research Institute · Phase 4, Interventional, and Health services research

How we know · 2 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute — 4 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · Ottawa Hospital Research Institute.

Enrollment
15th of 40
200 · median 121
Started
2016
with 8 others
Phase 4
20 of 44
3 open now
Registered
16th of 44
by date

Among the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, this one is the 15th largest by enrollment of the 40 interventional ones that give a count, is one of 9 that started in 2016, is one of 20 in phase 4, and was the 16th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Breast Neoplasms by Ottawa Hospital Research Institute, or all of them as a file.
02

Study summary

Several large adjuvant trastuzumab trials have demonstrated improved overall survival in participants with early stage breast cancer, with a 33% decrease in risk of death. However, retrospective analyses of participant outcomes in these trials have demonstrated increased risk of cardiotoxicity (i.e damage to the heart) in a small number of patients (4-8%).

At this time, investigators are unable to predict which participants are at increased risk of cardiac-related treatment complications. Currently all patients receive regular cardiac imaging throughout their one year of trastuzumab treatment.

At this time, the optimal monitoring schedule for trastuzumab-related cardiotoxicity remains unknown, and several published consensus guidelines are currently in use as standard of care.

03

Conditions studied

  • Breast Cancer

Keywords

  • cardiac toxicities
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed early stage -positive breast cancer
  • Planned trastuzumab therapy for early stage breast cancer
  • ≥18 years of age
  • Able to provide verbal consent
  • Normal (>53%) before trastuzumab therapy

Exclusion criteria

Exclusion Criteria:

  • to transthoracic echocardiography or
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    LVEF 3 month

    cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months

    Procedure: LVEF 3 month

  • Active comparator
    LVEF 4 month

    cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months

    Procedure: LVEF 4 month

Interventions

  • ProcedureLVEF 3 month

    cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months

  • ProcedureLVEF 4 month

    cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months

This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. LVEF Results

    Changes in Left Ventricular Ejection Fraction (LVEF) results compared to baseline (by echocardiography or MUGA) throughout the course of trastuzumab based therapy. LVEF is measured as a percentage. The outcome is a change in LVEF percentage (%).

    Time frame: Baseline to 1 year

Secondary outcomes

  1. Rates of Trastuzumab Delay and Discontinuation

    The number of participants who had a delay and/or discontinuation in trastuzumab treatment. Data was collected from physicians following clinic visits and from patient electronic medical records.

    Time frame: 1 year

  2. Referral to Cardiology

    The number of participants who were referred to cardiology. Data was collected from physicians following clinic visits, and from the patient's electronic medical record.

    Time frame: 1 year

  3. Rate of Cardiac Events

    The number of participants who experienced a decrease in ejection fraction (EF), congestive heart failure, or other cardiac events within the 1 year of study. Examples of other cardiac events include change in blood pressure, chest pain/shortness of breath, or irregular heartbeat. Data was collected/reported from physicians following clinic appointments, and from the patient's electronic medical record.

    Time frame: 1 year

07

Results

Posted Jul 14, 2025

Participant flow

Per Protocol Population
Participant flow — Per Protocol Population
MilestoneLVEF 3 MonthLVEF 4 Month
Started100100
Completed9897
Not completed23
Withdrew: Physician decision21
Withdrew: Participant decision02
Completed Study as Planned
Participant flow — Completed Study as Planned
MilestoneLVEF 3 MonthLVEF 4 Month
Started9897
Completed9088
Not completed89
Withdrew: Reason = lvef22
Withdrew: Protocol violation26
Withdrew: Metastatic disease30
Withdrew: Location11

Outcome measures

PrimaryLVEF Results

Changes in Left Ventricular Ejection Fraction (LVEF) results compared to baseline (by echocardiography or MUGA) throughout the course of trastuzumab based therapy. LVEF is measured as a percentage. The outcome is a change in LVEF percentage (%).

Time frame:
Baseline to 1 year
Reported as:
Median · LVEF Percentage (%)
LVEF Results
LVEF Percentage (%)LVEF 3 MonthLVEF 4 Month
LVEF Results-8 (-26 to 17)-6 (-33 to 10)
Statistical analysis
  • LVEF 3 Month vs LVEF 4 Month · Difference: -0.6 · 95% CI -2.5 to 1.2
SecondaryRates of Trastuzumab Delay and Discontinuation

The number of participants who had a delay and/or discontinuation in trastuzumab treatment. Data was collected from physicians following clinic visits and from patient electronic medical records.

Time frame:
1 year
Reported as:
Count of participants · Participants
Rates of Trastuzumab Delay and Discontinuation
ParticipantsLVEF 3 MonthLVEF 4 Month
Delay92
Discontinuation27
SecondaryReferral to Cardiology

The number of participants who were referred to cardiology. Data was collected from physicians following clinic visits, and from the patient's electronic medical record.

Time frame:
1 year
Reported as:
Count of participants · Participants
Referral to Cardiology
ParticipantsLVEF 3 MonthLVEF 4 Month
Referral to Cardiology1212
SecondaryRate of Cardiac Events

The number of participants who experienced a decrease in ejection fraction (EF), congestive heart failure, or other cardiac events within the 1 year of study. Examples of other cardiac events include change in blood pressure, chest pain/shortness of breath, or irregular heartbeat. Data was collected/reported from physicians following clinic appointments, and from the patient's electronic medical record.

Time frame:
1 year
Reported as:
Count of participants · Participants
Rate of Cardiac Events
ParticipantsLVEF 3 MonthLVEF 4 Month
Rate of Cardiac Events3124

Adverse events

Collected over All-cause mortality was monitored for 12 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LVEF 3 Month0/98 (0%)——
LVEF 4 Month0/97 (0%)——

Baseline characteristics

Age, Continuous
Age, Continuous(years)LVEF 3 MonthLVEF 4 MonthTotal
Mean55.4 ± 11.454.8 ± 11.355.1 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)LVEF 3 MonthLVEF 4 MonthTotal
Female9897195
Male000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)LVEF 3 MonthLVEF 4 MonthTotal
Count of participants——0
Baseline Left Ventricular Ejection Fraction (LVEF)
Baseline Left Ventricular Ejection Fraction (LVEF)(LVEF Percentage (%))LVEF 3 MonthLVEF 4 MonthTotal
Median65 (54 to 82)64 (54 to 76)65 (54 to 82)
Anthracycline-based chemotherapy
Anthracycline-based chemotherapy(Participants)LVEF 3 MonthLVEF 4 MonthTotal
Count of participants5350103
08

Study locations

4 sites
  • Southlake Regional Health Centre
    Newmarket, Ontario L3Y 2P9, Canada
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • The Ottawa Hospital Cancer Centre
    Ottawa, Ontario K2H 8L6, Canada
  • Thunder Bay Regional Health Sciences Centre
    Thunder Bay, Ontario P7B 6V4, Canada
09

References and documents

Publications

  • Dent S, Fergusson D, Aseyev O, Stober C, Pond G, Awan AA, McGee SF, Ng TL, Simos D, Vandermeer L, Saunders D, Hilton JF, Hutton B, Clemons M. A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. Curr Oncol. 2021 Dec 3;28(6):5073-5083. doi: 10.3390/curroncol28060427. PubMed 34940066 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of May 2020 and a completion of Jul 2020. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2025, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2016
First posted
Mar 2, 2016
Start
Jun 2016
Primary completionActual
May 2020
CompletionActual
Jul 2020
Results first posted
Jul 14, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02696707
Responsible party
Sponsor
First posted
Mar 2, 2016
Start date
Jun 2016
Primary completion
May 2020
Completion
Jul 2020
Results posted
Jul 14, 2025
Last update
Dec 18, 2025

Study contacts

Olexiy Aseyey, MD
principal investigator · The Ottawa Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion